Webcasts - Thursday, July 3, 2014

Print
For Wednesday's Webcasts Click here

ENDOUROLOGY
Optimum treatment of lower caliceal stones – Has the last world been said?
ESWL: Shimon Meretyk, Israel
PCNL: Mordechai Duvdevani, Israel
RIRS: Scott Hubosky, USA

ENDOUROLOGY
Management of ureteral strictures
Panelists:
Scott Hubosky, USA
Ivan Grunberger, USA
David Lifshitz, Israel
Mario Sofer, Israel
Harry Winkler, Israel
CONTEMPORARY ISSUES IN RADIOTHERAPY FOR PROSTATE CANCER
Stereotactic Ablative Radiotherapy and other Hypo-fractionated regiments: a new standard of card for low and intermediate risk prostate cancer?
Pro: Zvi Symon, Israel
Con: Howard Sandler, USA

CONTEMPORARY ISSUES IN RADIOTHERAPY FOR PROSTATE CANCER
Dose escalation strategies: is there still a role for combining brachytherapy and external beam RT in intermediate to high risk prostate cancer?
Pro: Michael Zelefsky, USA
Con: Howard Sandler, USA

CONTEMPORARY ISSUES IN RADIOTHERAPY FOR PROSTATE CANCER
Salvage therapy
How to improve outcomes:
Michael Zelefsky, USA
 HONORARY GUEST SPEAKER
The changing international challenges for Israel
Mr. Malcolm Hoenlein
Executive Vice Chairman of The Conference of Presidents of Major American Jewish Organizations
PROSTATE CANCER:
10 YEARS FROM NOW
Based upon my knowledge and experience, my educated guess is that:
Targeted technique will replace the standard random prostate biopsy
E. David Crawford, USA
Risk grouping will be modified
Leonard Gomella, USA
PSA-based screening will be replaced by alternative strategies
Joel Nelson, USA
We'll see a significant decline in prostate cancer mortality
David Margel, Israel
Cyberknife will become an alternative to brachytherapy and surgery
Michael Zelefsky, USA
WHAT DO WE AGREE/DISAGREE ABOUT INCLUDING ACTIVE SURVEILLANCE IN THE MANAGEMENT OF PROSTATE CANCER?
Moderator: Mark Soloway, USA
Panelists:
Neil Fleshner, Canada
Laurence Klotz, Canada
Haim Matzkin, Israel
Claude Schulman, Belgium
Mark Stovsky, USA
Amnon Zisman, Israel
NEW CONCEPTS IN CASTRATE RESISTANT PROSTATE CANCER (CRPC)
Use of Abiraterone for symptomatic and asymptomatic metastases
Menachem Laufer, Israel
Targeted systemic approaches
Mario Eisenberger, USA & Cora Sternberg, Italy
Immunotherapy
Leonard Gomella, USA
Stem cells
George Thalmann, Switzerland
Targeted Irradiation (Radionuclide treatment)
Howard Sandler, USA
ANATOMIC APPROACH TO RADICAL PROSTATECTOMY:
OPEN VERSUS LAPORASCOPIC VERSUS ROBOT
How I do it and why I believe it affects the outcomes:
Control of the Santorini's plexus
Open: Marc Zerbib, France
Robot: Claude Abbou, France
Robot: Vito Pansadoro, Italy
ANATOMIC APPROACH TO RADICAL PROSTATECTOMY:
OPEN VERSUS LAPORASCOPIC VERSUS ROBOT
How I do it and why I believe it affects the outcomes:
Bladder neck and seminal vesicles dissection
Open: Robert Nam, Canada
Laporascopic: Shin Egawa, Japan
Robot: Kevin Slawin, USA
Robot: Vito Pansadoro, Italy
ANATOMIC APPROACH TO RADICAL PROSTATECTOMY:
OPEN VERSUS LAPORASCOPIC VERSUS ROBOT
How I do it and why I believe it affects the outcomes:
Neuro-vascular preservation
Open: Robert Nam, Canada
Laporascopic: Shin Egawa, Japan
Robot: Gilad Amiel, USA
Robot: Vito Pansadoro, Italy
 
ANATOMIC APPROACH TO RADICAL PROSTATECTOMY:
OPEN VERSUS LAPORASCOPIC VERSUS ROBOT
How I do it and why I believe it affects the outcomes:
Vesico-urethral anastomosis
Open: Marc Zerbib, France
Laporascopic: Shin Egawa, Japan
Robot: Claude Abbou, France
Robot: Vito Pansadoro, Italy